Redox environment and its meaning for breast cancer cells fate

Current Cancer Drug Targets

Volumn 11, Issue 4, 2011, Pages 479-495

  Ostrakhovitch, E A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Breast cancer cells; Drug resistance; Intracellular redox state; Redox signaling

Indexed keywords

BETA ACTIN; COPPER ZINC SUPEROXIDE DISMUTASE; DUAL OXIDASE 1; DUAL OXIDASE 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROGEN PEROXIDE; MAMMALIAN TARGET OF RAPAMYCIN; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P21; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RISK; CELL DIFFERENTIATION; CELL FATE; CELL GROWTH; CELL PH; CELL SPREADING; CELL SURVIVAL; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; OXIDATION REDUCTION POTENTIAL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; OXIDATION-REDUCTION; TUMOR MICROENVIRONMENT;

EID: 79955593573     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911795538129     Document Type: Review

References (213)

1. Pagani, O.; Senkus, E.; Wood, W.; Colleoni, M.; Cufer, T.; Kyriakides, S.; Costa, A.; Winer, E. P.; Cardoso, F. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J. Natl. Cancer Inst. 2010, 102, 456-463.
2. Nakamura, H.; Nakamura, K.; Yodoi, J. Redox regulation of cellular activation. Annu. Rev. Immunol. 1997, 15, 351-369.
3. Rokutan, K.; Hirakawa, T.; Teshima, S.; Honda, S.; Kishi, K. Glutathione depletion impairs transcriptional activation of heat shock genes in primary cultures of guinea pig gastric mucosal cells. J. Clin. Invest. 1996, 97, 2242-2250.
4. Wu, X.; Bishopric, N. H.; Discher, D. J.; Murphy, B. J.; Webster, K. A. Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol. Cell Biol. 1996, 16, 1035-1046.
5. Storz, P. Reactive oxygen species in tumor progression. Front. Biosci. 2005, 10, 1881-1896.
6. Abate, C.; Patel, L.; Rauscher, F. J., III; Curran, T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990, 249, 1157-1161.
7. Tell, G.; Pines, A.; Paron, I.; D'Elia, A.; Bisca, A.; Kelley, M. R.; Manzini, G.; Damante, G. Redox effector factor-1 regulates the activity of thyroid transcription factor 1 by controlling the redox state of the N transcriptional activation domain. J. Biol. Chem. 2002, 277, 14564-14574.
8. Hirota, K.; Matsui, M.; Murata, M.; Takashima, Y.; Cheng, F. S.; Itoh, T.; Fukuda, K.; Yodoi, J. Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-kappaB, AP-1, and CREB activation in HEK293 cells. Biochem. Biophys. Res. Commun. 2000, 274, 177-182.
9. Wei, S. J.; Botero, A.; Hirota, K.; Bradbury, C. M.; Markovina, S.; Laszlo, A.; Spitz, D. R.; Goswami, P. C.; Yodoi, J.; Gius, D. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res. 2000, 60, 6688-6695.
10. Meplan, C.; Richard, M. J.; Hainaut, P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 2000, 19, 5227-5236.
11. Flint, K. J.; Jones, N. C. Differential regulation of three members of the ATF/CREB family of DNA-binding proteins. Oncogene 1991, 6, 2019-2026.
12. Huang, R. P.; Liu, C.; Fan, Y.; Mercola, D.; Adamson, E. D. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res. 1995, 55, 5054-5062.
13. Fujii, M.; Saijoh, K.; Kobayashi, T.; Fujii, S.; Lee, M. J.; Sumino, K. Analysis of bovine selenoprotein P-like protein gene and availability of metal responsive element (MRE) located in its promoter. Gene 1997, 199, 211-217.
14. Leslie, N. R.; Bennett, D.; Lindsay, Y. E.; Stewart, H.; Gray, A.; Downes, C. P. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003, 22, 5501-5510.
15. Kallergi, G.; Mavroudis, D.; Georgoulias, V.; Stournaras, C. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol. Med. 2007, 13, 79-88.
16. Kallergi, G.; Agelaki, S.; Kalykaki, A.; Stournaras, C.; Mavroudis, D.; Georgoulias, V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res. 2008, 10, R80.
17. Sivaraman, V. S.; Wang, H.; Nuovo, G. J.; Malbon, C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 1997, 99, 1478-1483.
18. Adeyinka, A.; Nui, Y.; Cherlet, T.; Snell, L.; Watson, P. H.; Murphy, L. C. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin. Cancer Res. 2002, 8, 1747-1753.
19. Mueller, H.; Flury, N.; Eppenberger-Castori, S.; Kueng, W.; David, F.; Eppenberger, U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int. J. Cancer 2000, 89, 384-388.
20. Singh, B.; Reddy, P. G.; Goberdhan, A.; Walsh, C.; Dao, S.; Ngai, I.; Chou, T. C.; Charoenrat, P.; Levine, A. J.; Rao, P. H.; Stoffel, A. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 2002, 16, 984-993.
21. Bouali, S.; Chretien, A. S.; Ramacci, C.; Rouyer, M.; Marchal, S.; Galenne, T.; Juin, P.; Becuwe, P.; Merlin, J. L. P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Ther. 2009, 16, 498-507.
22. Drakos, E.; Atsaves, V.; Li, J.; Leventaki, V.; Andreeff, M.; Medeiros, L. J.; Rassidakis, G. Z. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 2009, 23, 784-790.
23. Astanehe, A.; Arenillas, D.; Wasserman, W. W.; Leung, P. C.; Dunn, S. E.; Davies, B. R.; Mills, G. B.; Auersperg, N. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J. Cell Sci. 2008, 121, 664-674.
24. Mayo, L. D.; Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U.S. A 2001, 98, 11598-11603.
25. McCubrey, J. A.; Steelman, L. S.; Abrams, S. L.; Lee, J. T.; Chang, F.; Bertrand, F. E.; Navolanic, P. M.; Terrian, D. M.; Franklin, R. A.; D'Assoro, A. B.; Salisbury, J. L.; Mazzarino, M. C.; Stivala, F.; Libra, M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 2006, 46, 249-279.
26. Pearson, G. W.; Hunter, T. PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture. Breast Cancer Res. 2009, 11, R29.
27. Abshire, M. K.; Devor, D. E.; Diwan, B. A.; Shaughnessy, J. D., Jr.; Waalkes, M. P. In vitro exposure to cadmium in rat L6 myoblasts can result in both enhancement and suppression of malignant progression in vivo. Carcinogenesis 1996, 17, 1349-1356.
28. Ross, S. H.; Lindsay, Y.; Safrany, S. T.; Lorenzo, O.; Villa, F.; Toth, R.; Clague, M. J.; Downes, C. P.; Leslie, N. R. Differential redox regulation within the PTP superfamily. Cell Signal. 2007, 19, 1521-1530.
29. Rzymowska, J.; Dyrda, Z. Enzyme activities and level of SH groups in breast carcinomas. Int. J. Biochem. 1993, 25, 1331-1334.
30. Abou Ghalia, A. H.; Fouad, I. M. Glutathione and its metabolizing enzymes in patients with different benign and malignant diseases. Clin. Biochem. 2000, 33, 657-662.
31. Buser, K.; Joncourt, F.; Altermatt, H. J.; Bacchi, M.; Oberli, A.; Cerny, T. Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann. Oncol. 1997, 8, 335-341.
32. Kumaraguruparan, R.; Subapriya, R.; Viswanathan, P.; Nagini, S. Tissue lipid peroxidation and antioxidant status in patients with adenocarcinoma of the breast. Clin. Chim. Acta 2002, 325, 165-170.
33. Agnoletto, M. H.; Guecheva, T. N.; Donde, F.; de Oliveira, A. F.; Franke, F.; Cassini, C.; Salvador, M.; Henriques, J. A.; Saffi, J. Association of low repair efficiency with high hormone receptors expression and SOD activity in breast cancer patients. Clin. Biochem. 2007, 40, 1252-1258.
34. Punnonen, K.; Ahotupa, M.; Asaishi, K.; Hyoty, M.; Kudo, R.; Punnonen, R. Antioxidant enzyme activities and oxidative stress in human breast cancer. J. Cancer Res. Clin. Oncol. 1994, 120, 374-377.
35. Pucci-Minafra, I.; Cancemi, P.; Fontana, S.; Minafra, L.; Feo, S.; Becchi, M.; Freyria, A. M.; Minafra, S. Expanding the protein catalogue in the proteome reference map of human breast cancer cells. Proteomics 2006, 6, 2609-2625.
36. Pucci-Minafra, I.; Fontana, S.; Cancemi, P.; Alaimo, G.; Minafra, S. Proteomic patterns of cultured breast cancer cells and epithelial mammary cells. Ann. N.Y. Acad. Sci. 2002, 963, 122-139.
37. Mense, S. M.; Remotti, F.; Bhan, A.; Singh, B.; El Tamer, M.; Hei, T. K.; Bhat, H. K. Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol. Appl. Pharmacol. 2008, 232, 78-85.
38. el Bouhtoury, F.; Keller, J. M.; Colin, S.; Parache, R. M.; Dauca, M. Peroxisomal enzymes in normal and tumoral human breast. J. Pathol. 1992, 166, 27-35.
39. Portakal, O.; Ozkaya, O.; Erden, I. M.; Bozan, B.; Kosan, M.; Sayek, I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin. Biochem. 2000, 33, 279-284.
40. Anuszewska, E. L.; Gruber, B. M.; Koziorowska, J. H. Studies on adaptation to adriamycin in cells pretreated with hydrogen peroxide. Biochem. Pharmacol. 1997, 54, 597-603.
41. Bianchi, M. S.; Bianchi, N. O.; Bolzan, A. D. Superoxide dismutase activity and superoxide dismutase-1 gene methylation in normal and tumoral human breast tissues. Cancer Genet. Cytogenet. 1992, 59, 26-29.
42. Starcevic, S. L.; Diotte, N. M.; Zukowski, K. L.; Cameron, M. J.; Novak, R. F. Oxidative DNA damage and repair in a cell lineage model of human proliferative breast disease (PBD). Toxicol. Sci. 2003, 75, 74-81.
43. Folgueira, M. A.; Carraro, D. M.; Brentani, H.; Patrao, D. F.; Barbosa, E. M.; Netto, M. M.; Caldeira, J. R.; Katayama, M. L.; Soares, F. A.; Oliveira, C. T.; Reis, L. F.; Kaiano, J. H.; Camargo, L. P.; Vencio, R. Z.; Snitcovsky, I. M.; Makdissi, F. B.; Silva, P. J.; Goes, J. C.; Brentani, M. M. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin. Cancer Res. 2005, 11, 7434-7443.
44. Kattan, Z.; Minig, V.; Leroy, P.; Dauca, M.; Becuwe, P. Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res. Treat. 2008, 108, 203-215.
45. Weydert, C. J.; Waugh, T. A.; Ritchie, J. M.; Iyer, K. S.; Smith, J. L.; Li, L.; Spitz, D. R.; Oberley, L. W. Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. Free Radic. Biol. Med. 2006, 41, 226-237.
46. Bors, W.; Saran, M.; Lengfelder, E.; Michel, C.; Fuchs, C.; Frenzel, C. Detection of oxygen radicals in biological reactions. Photochem. Photobiol. 1978, 28, 629-638.
47. Bielski, B. H. J.; Shiue, G. G.; Bajuk, S. Reduction of Nitro Blue Tetrazolium by Co2-and O-2-Radicals. J. Phy. Chem. 1980, 84, 830-833.
48. Bae, I.; Fan, S.; Meng, Q.; Rih, J. K.; Kim, H. J.; Kang, H. J.; Xu, J.; Goldberg, I. D.; Jaiswal, A. K.; Rosen, E. M. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 2004, 64, 7893-7909.
49. Murata, H.; Ihara, Y.; Nakamura, H.; Yodoi, J.; Sumikawa, K.; Kondo, T. Glutaredoxin exerts an antiapoptotic effect by regulating the redox state of Akt. J. Biol. Chem. 2003, 278, 50226-50233.
50. De Larco, J. E.; Park, C. A.; Dronava, H.; Furcht, L. T. Paradoxical roles for antioxidants in tumor prevention and eradication. Cancer Biol. Ther. 2010, 9, 362-370.
51. Krezel, A.; Hao, Q.; Maret, W. The zinc/thiolate redox biochemistry of metallothionein and the control of zinc ion fluctuations in cell signaling. Arch. Biochem. Biophys. 2007, 463, 188-200.
52. Kroncke, K. D.; Klotz, L. O. Zinc fingers as biologic redox switches? Antioxid. Redox. Signal. 2009, 11, 1015-1027.
53. Cortese, M. M.; Suschek, C. V.; Wetzel, W.; Kroncke, K. D.; Kolb-Bachofen, V. Zinc protects endothelial cells from hydrogen peroxide via Nrf2-dependent stimulation of glutathione biosynthesis. Free Radic. Biol. Med. 2008, 44, 2002-2012.
54. Geraki, K.; Farquharson, M. J.; Bradley, D. A. Concentrations of Fe, Cu and Zn in breast tissue: a synchrotron XRF study. Phys. Med. Biol. 2002, 47, 2327-2339.
55. Geraki, K.; Farquharson, M. J.; Bradley, D. A. X-ray fluorescence and energy dispersive x-ray diffraction for the quantification of elemental concentrations in breast tissue. Phys. Med. Biol. 2004, 49, 99-110.
56. Kagara, N.; Tanaka, N.; Noguchi, S.; Hirano, T. Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells. Cancer Sci. 2007, 98, 692-697.
57. Santoliquido, P. M.; Southwick, H. W.; Olwin, J. H. Trace metal levels in cancer of the breast. Surg. Gynecol. Obstet. 1976, 142, 65-70.
58. Margalioth, E. J.; Schenker, J. G.; Chevion, M. Copper and zinc levels in normal and malignant tissues. Cancer 1983, 52, 868-872.
59. Hakama, M.; Hakulinen, T.; Kenward, M. G.; Aaran, R. K.; Aromaa, A.; Knekt, P.; Nikkari, T.; Teppo, L.; Peto, R. Blood biochemistry and the risk of cancer. Acta Oncol. 2004, 43, 667-674.
60. Ostrakhovitch, E. A.; Olsson, P. E.; von Hofsten, J.; Cherian, M. G. P53 mediated regulation of metallothionein transcription in breast cancer cells. J. Cell Biochem. 2007, 102, 1571-1583.
61. Manning, D. L.; McClelland, R. A.; Gee, J. M.; Chan, C. M.; Green, C. D.; Blamey, R. W.; Nicholson, R. I. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur. J. Cancer 1993, 29A, 1462-1468.
62. Manning, D. L.; Robertson, J. F.; Ellis, I. O.; Elston, C. W.; McClelland, R. A.; Gee, J. M.; Jones, R. J.; Green, C. D.; Cannon, P.; Blamey, R. W. Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement. Eur. J. Cancer 1994, 30A, 675-678.
63. Taylor, K. M.; Vichova, P.; Jordan, N.; Hiscox, S.; Hendley, R.; Nicholson, R. I. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormoneresistant breast cancer Cells. Endocrinology 2008, 149, 4912-4920.
64. Hatfield, W. E. (2010) Chemistry of copper. In: Handbook of copper compounds and applications., pp. 12-31. Editor: H.W. Richardson.
65. Overvad, K.; Wang, D. Y.; Olsen, J.; Allen, D. S.; Thorling, E. B.; Bulbrook, R. D.; Hayward, J. L. Copper in human mammary carcinogenesis: a case-cohort study. Am. J. Epidemiol. 1993, 137, 409-414.
66. Ionescu, J. G.; Novotny, J.; Stejskal, V.; Latsch, A.; Blaurock-Busch, E.; Eisenmann-Klein, M. Increased levels of transition metals in breast cancer tissue. Neuro. Endocrinol. Lett. 2006, 27 Suppl 1, 36-39.
67. Zowczak, M.; Iskra, M.; Paszkowski, J.; Manczak, M.; Torlinski, L.; Wysocka, E. Oxidase activity of ceruloplasmin and concentrations of copper and zinc in serum of cancer patients. J. Trace Elem. Med. Biol. 2001, 15, 193-196.
68. Farquharson, M. J.; Al Ebraheem, A.; Falkenberg, G.; Leek, R.; Harris, A. L.; Bradley, D. A. The distribution of trace elements Ca, Fe, Cu and Zn and the determination of copper oxidation state in breast tumour tissue using muSRXRF and muXANES. Phys. Med. Biol. 2008, 53, 3023-3037.
69. Fuchs, A. G.; Mariotto, R.; de Lustig, E. S. Serum and tissue copper content in two mammary adenocarcinomas with different biological behaviour. Eur. J. Cancer Clin. Oncol. 1986, 22, 1347-1352.
70. Rizk, S. L.; Sky-Peck, H. H. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 1984, 44, 5390-5394.
71. Sharma, K.; Mittal, D. K.; Kesarwani, R. C.; Kamboj, V. P.; Chowdhery Diagnostic and prognostic significance of serum and tissue trace elements in breast malignancy. Indian J. Med. Sci. 1994, 48, 227-232.
72. Borella, P.; Bargellini, A.; Caselgrandi, E.; Piccinini, L. Observations on the use of plasma, hair and tissue to evaluate trace element status in cancer. J. Trace Elem. Med. Biol. 1997, 11, 162-165.
73. Kuo, H. W.; Chen, S. F.; Wu, C. C.; Chen, D. R.; Lee, J. H. Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol. Trace Elem. Res. 2002, 89, 1-11.
74. Majumder, S.; Chatterjee, S.; Pal, S.; Biswas, J.; Efferth, T.; Choudhuri, S. K. The role of copper in drug-resistant murine and human tumors. Biometals 2009, 22, 377-384.
75. Al Ebraheem, A.; Farquharson, M. J.; Ryan, E. The evaluation of biologically important trace metals in liver, kidney and breast tissue. Appl. Radiat. Isot. 2009, 67, 470-474.
76. Takahashi, K.; Yoshioka, O.; Matsuda, A.; Umezawa, H. Intracellular reduction of the cupric ion of bleomycin copper complex and transfer of the cuprous ion to a cellular protein. J. Antibiot. (Tokyo) 1977, 30, 861-869.
77. Fuchs, A. G.; de Lustig, E. S. Copper histochemistry of 5 murine tumors and their respective metastases. Tumour Biol. 1989, 10, 38-45.
78. Stein, T.; Salomonis, N.; Nuyten, D. S.; van de Vijver, M. J.; Gusterson, B. A. A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasis. J. Mammary Gland Biol. Neoplasia 2009, 14, 99-116.
79. Carri, M. T.; Galiazzo, F.; Ciriolo, M. R.; Rotilio, G. Evidence for co-regulation of Cu, Zn superoxide dismutase and metallothionein gene expression in yeast through transcriptional control by copper via the ACE 1 factor. FEBS Lett. 1991, 278, 263-266.
80. Yoo, H. Y.; Chang, M. S.; Rho, H. M. Heavy metal-mediated activation of the rat Cu/Zn superoxide dismutase gene via a metalresponsive element. Mol. Gen. Genet. 1999, 262, 310-313.
81. Kimura, T.; Itoh, N.; Sone, T.; Tanaka, K.; Isobe, M. C-terminal deletion mutant of MRE-binding transcription factor-1 inhibits MRE-driven gene expression. J. Cell Biochem. 2004, 93, 609-618.
82. Samet, J. M.; Graves, L. M.; Quay, J.; Dailey, L. A.; Devlin, R. B.; Ghio, A. J.; Wu, W.; Bromberg, P. A.; Reed, W. Activation of MAPKs in human bronchial epithelial cells exposed to metals. Am. J. Physiol. 1998, 275, L551-L558.
83. Chang, M. S.; Yoo, H. Y.; Rho, H. M. Positive and negative regulatory elements in the upstream region of the rat Cu/Znsuperoxide dismutase gene. Biochem. J. 1999, 339 (Pt 2), 335-341.
84. Mattie, M. D.; Freedman, J. H. Copper-inducible transcription: regulation by metal-and oxidative stress-responsive pathways. Am. J. Physiol. Cell Physiol. 2004, 286, C293-C301.
85. Ostrakhovitch, E. A.; Cherian, M. G. Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: the lack of effect of ERK in p53 mediated copper induced apoptosis. J. Cell Biochem. 2005, 95, 1120-1134.
86. Kanzaki, A.; Toi, M.; Neamati, N.; Miyashita, H.; Oubu, M.; Nakayama, K.; Bando, H.; Ogawa, K.; Mutoh, M.; Mori, S.; Terada, K.; Sugiyama, T.; Fukumoto, M.; Takebayashi, Y. Coppertransporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn. J. Cancer Res. 2002, 93, 70-77.
87. Martinez-Balibrea, E.; Martinez-Cardus, A.; Musulen, E.; Gines, A.; Manzano, J. L.; Aranda, E.; Plasencia, C.; Neamati, N.; Abad, A. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int. J. Cancer 2009, 124, 2905-2910.
88. Maret, W.; Vallee, B. L. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc. Natl. Acad. Sci. U.S. A 1998, 95, 3478-3482.
89. Jacob, C.; Maret, W.; Vallee, B. L. Control of zinc transfer between thionein, metallothionein, and zinc proteins. Proc. Natl. Acad. Sci. U.S. A 1998, 95, 3489-3494.
90. Maret, W. Metallothionein redox biology in the cytoprotective and cytotoxic functions of zinc. Exp. Gerontol. 2008, 43, 363-369.
91. Nielsen, A. E.; Bohr, A.; Penkowa, M. The Balance between life and death of cells: Roles of metallothioneins. Biomark. Insights. 2007, 1, 99-111.
92. Cherian, M. G.; Jayasurya, A.; Bay, B. H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res. 2003, 533, 201-209.
93. Cai, L.; Cherian, M. G. Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper-or cadmium-metallothioneins. Toxicol. Lett. 2003, 136, 193-198.
94. Tamai, K. T.; Gralla, E. B.; Ellerby, L. M.; Valentine, J. S.; Thiele, D. J. Yeast and mammalian metallothioneins functionally substitute for yeast copper-zinc superoxide dismutase. Proc. Natl. Acad. Sci. U.S. A 1993, 90, 8013-8017.
95. Haidara, K.; Moffatt, P.; Denizeau, F. Metallothionein induction attenuates the effects of glutathione depletors in rat hepatocytes. Toxicol. Sci. 1999, 49, 297-305.
96. Maret, W.; Larsen, K. S.; Vallee, B. L. Coordination dynamics of biological zinc "clusters" in metallothioneins and in the DNAbinding domain of the transcription factor Gal4. Proc. Natl. Acad. Sci. U.S. A 1997, 94, 2233-2237.
97. Meplan, C.; Richard, M. J.; Hainaut, P. Redox signalling and transition metals in the control of the p53 pathway. Biochem. Pharmacol. 2000, 59, 25-33.
98. Ostrakhovitch, E. A.; Olsson, P. E.; Jiang, S.; Cherian, M. G. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett. 2006, 580, 1235-1238.
99. Hengstler, J. G.; Pilch, H.; Schmidt, M.; Dahlenburg, H.; Sagemuller, J.; Schiffer, I.; Oesch, F.; Knapstein, P. G.; Kaina, B.; Tanner, B. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int. J. Cancer 2001, 95, 121-127.
100. Jayasurya, A.; Bay, B. H.; Yap, W. M.; Tan, N. G. Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br. J. Cancer 2000, 82, 1198-1203.
101. Jin, R.; Chow, V. T.; Tan, P. H.; Dheen, S. T.; Duan, W.; Bay, B. H. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002, 23, 81-86.
102. Theocharis, S. E.; Margeli, A. P.; Klijanienko, J. T.; Kouraklis, G. P. Metallothionein expression in human neoplasia. Histopathology 2004, 45, 103-118.
103. Yap, X.; Tan, H. Y.; Huang, J.; Lai, Y.; Yip, G. W.; Tan, P. H.; Bay, B. H. Over-expression of metallothionein predicts chemoresistance in breast cancer. J. Pathol. 2009, 217, 563-570.
104. Smith, D. J.; Jaggi, M.; Zhang, W.; Galich, A.; Du, C.; Sterrett, S. P.; Smith, L. M.; Balaji, K. C. Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology 2006, 67, 1341-1347.
105. Ohshio, G.; Imamura, T.; Okada, N.; Wang, Z. H.; Yamaki, K.; Kyogoku, T.; Suwa, H.; Yamabe, H.; Imamura, M. Immunohistochemical study of metallothionein in pancreatic carcinomas. J. Cancer Res. Clin. Oncol. 1996, 122, 351-355.
106. Fresno, M.; Wu, W.; Rodriguez, J. M.; Nadji, M. Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch. A Pathol. Anat. Histopathol. 1993, 423, 215-219.
107. Bruewer, M.; Schmid, K. W.; Krieglstein, C. F.; Senninger, N.; Schuermann, G. Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma. World J. Surg. 2002, 26, 726-731.
108. Friedline, J. A.; Garrett, S. H.; Somji, S.; Todd, J. H.; Sens, D. A. Differential expression of the MT-1E gene in estrogen-receptorpositive and-negative human breast cancer cell lines. Am. J. Pathol. 1998, 152, 23-27.
109. Jin, R.; Bay, B. H.; Chow, V. T.; Tan, P. H.; Lin, V. C. Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. Br. J. Cancer 2000, 83, 319-323.
110. Fan, L. Z.; Cherian, M. G. Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br. J. Cancer 2002, 87, 1019-1026.
111. Shaulian, E.; Zauberman, A.; Ginsberg, D.; Oren, M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell Biol. 1992, 12, 5581-5592.
112. Meskel, H. H.; Cherian, M. G.; Martinez, V. J.; Veinot, L. A.; Frei, J. V. Metallothionein as an epithelial proliferative compartment marker for DNA flow cytometry. Mod. Pathol. 1993, 6, 755-760.
113. Nagel, W. W.; Vallee, B. L. Cell cycle regulation of metallothionein in human colonic cancer cells. Proc. Natl. Acad. Sci. U.S. A 1995, 92, 579-583.
114. Apostolova, M. D.; Ivanova, I. A.; Cherian, M. G. Signal transduction pathways, and nuclear translocation of zinc and metallothionein during differentiation of myoblasts. Biochem. Cell Biol. 2000, 78, 27-37.
115. Takahashi, Y.; Ogra, Y.; Suzuki, K. T. Nuclear trafficking of metallothionein requires oxidation of a cytosolic partner. J. Cell Physiol. 2005, 202, 563-569.
116. Jin, R.; Huang, J.; Tan, P. H.; Bay, B. H. Clinicopathological significance of metallothioneins in breast cancer. Pathol. Oncol. Res. 2004, 10, 74-79.
117. Kojima, I.; Tanaka, T.; Inagi, R.; Nishi, H.; Aburatani, H.; Kato, H.; Miyata, T.; Fujita, T.; Nangaku, M. Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int. 2009, 75, 268-277.
118. Pitteri, S. J.; Faca, V. M.; Kelly-Spratt, K. S.; Kasarda, A. E.; Wang, H.; Zhang, Q.; Newcomb, L.; Krasnoselsky, A.; Paczesny, S.; Choi, G.; Fitzgibbon, M.; McIntosh, M. W.; Kemp, C. J.; Hanash, S. M. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J. Proteome Res. 2008, 7, 1481-1489.
119. Patwardhan, A. J.; Strittmatter, E. F.; Camp, D. G.; Smith, R. D.; Pallavicini, M. G. Comparison of normal and breast cancer cell lines using proteome, genome, and interactome data. J. Proteome Res. 2005, 4, 1952-1960.
120. Sandhu, C.; Connor, M.; Kislinger, T.; Slingerland, J.; Emili, A. Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. J. Proteome Res. 2005, 4, 674-689.
121. Wimmer, U.; Wang, Y.; Georgiev, O.; Schaffner, W. Two major branches of anti-cadmium defense in the mouse: MTF-1/metallothioneins and glutathione. Nucleic Acids Res. 2005, 33, 5715-5727.
122. Brown, N. S.; Bicknell, R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3, 323-327.
123. Aykin-Burns, N.; Ahmad, I. M.; Zhu, Y.; Oberley, L. W.; Spitz, D. R. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem. J. 2009, 418, 29-37.
124. Ostrakhovitch, E. A.; Li, S. S. NIP1/DUOXA1 expression in epithelial breast cancer cells: regulation of cell adhesion and actin dynamics. Breast Cancer Res. Treat. 2010, 119, 773-786.
125. Desouki, M. M.; Kulawiec, M.; Bansal, S.; Das, G. M.; Singh, K. K. Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. Cancer Biol. Ther. 2005, 4, 1367-1373.
126. Edens, W. A.; Sharling, L.; Cheng, G.; Shapira, R.; Kinkade, J. M.; Lee, T.; Edens, H. A.; Tang, X.; Sullards, C.; Flaherty, D. B.; Benian, G. M.; Lambeth, J. D. Tyrosine cross-linking of extracellular matrix is catalyzed by Duox, a multidomain oxidase/peroxidase with homology to the phagocyte oxidase subunit gp91phox. J. Cell Biol. 2001, 154, pp. 879-891.
127. El Hassani, R. A.; Benfares, N.; Caillou, B.; Talbot, M.; Sabourin, J. C.; Belotte, V.; Morand, S.; Gnidehou, S.; Agnandji, D.; Ohayon, R.; Kaniewski, J.; Noel-Hudson, M. S.; Bidart, J. M.; Schlumberger, M.; Virion, A.; Dupuy, C. Dual oxidase2 is expressed all along the digestive tract. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288, G933-G942.
128. Forteza, R.; Salathe, M.; Miot, F.; Forteza, R.; Conner, G. E. Regulated hydrogen peroxide production by Duox in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2005, 32, 462-469.
129. Schwarzer, C.; Machen, T. E.; Illek, B.; Fischer, H. NADPH oxidase-dependent acid production in airway epithelial cells. J. Biol. Chem. 2004, 279, 36454-36461.
130. Lambeth, J. D.; Kawahara, T.; Diebold, B. Regulation of Nox and Duox enzymatic activity and expression. Free Radic. Biol. Med. 2007, 43, 319-331.
131. Sumimoto, H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008, 275, 3249-3277.
132. Grasberger, H.; Refetoff, S. Identification of the maturation factor for dual oxidase. Evolution of an eukaryotic operon equivalent. J. Biol. Chem. 2006, 281, 18269-18272.
133. Xing, G.; Romanyukha, A.; Bunger, R. Reactive oxygen species (ROS) in human breast cancer cell lines differing in malignancy: An electron paramagnetic resonance (EPR) study. FASEB J. 2008, 22, 794.10.
134. Maeda, H.; Hori, S.; Ohizumi, H.; Segawa, T.; Kakehi, Y.; Ogawa, O.; Kakizuka, A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death. Differ. 2004, 11, 737-746.
135. Wartenberg, M.; Ling, F. C.; Schallenberg, M.; Baumer, A. T.; Petrat, K.; Hescheler, J.; Sauer, H. Down-regulation of intrinsic Pglycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J. Biol. Chem. 2001, 276, 17420-17428.
136. Polyak, K.; Xia, Y.; Zweier, J. L.; Kinzler, K. W.; Vogelstein, B. A model for p53-induced apoptosis. Nature 1997, 389, 300-305.
137. Rivera, A.; Maxwell, S. A. The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J. Biol. Chem. 2005, 280, 29346-29354.
138. Matoba, S.; Kang, J.G.; Patino, W.D.; Wragg, A.; Boehm, M.; Gavrilova, O.; Hurley, P.J.; Bunz, F.; Hwang, P.M. p53 regulates mitochondrial respiration. Science 2006, 312, pp. 1650-1653.
139. Drane, P.; Bravard, A.; Bouvard, V.; May, E. Reciprocal downregulation of p53 and SOD2 gene expression-implication in p53 mediated apoptosis. Oncogene 2001, 20, 430-439.
140. Dhar, S. K.; Xu, Y.; Chen, Y.; St Clair, D. K. Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression. J. Biol. Chem. 2006, 281, 21698-21709.
141. Sablina, A. A.; Budanov, A. V.; Ilyinskaya, G. V.; Agapova, L. S.; Kravchenko, J. E.; Chumakov, P. M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 2005, 11, 1306-1313.
142. Brand, K. A.; Hermfisse, U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 1997, 11, 388-395.
143. Gottlob, K.; Majewski, N.; Kennedy, S.; Kandel, E.; Robey, R. B.; Hay, N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001, 15, 1406-1418.
144. Majewski, N.; Nogueira, V.; Bhaskar, P.; Coy, P. E.; Skeen, J. E.; Gottlob, K.; Chandel, N. S.; Thompson, C. B.; Robey, R. B.; Hay, N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 2004, 16, 819-830.
145. Rathmell, J.C.; Fox, C.J.; Plas, D.R.; Hammerman, P.S.; Cinalli, R.M.; Thompson, C.B. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factorindependent survival. Mol. Cell Biol. 2003, 23, pp. 7315-7328.
146. Pelicano, H.; Xu, R. H.; Du, M.; Feng, L.; Sasaki, R.; Carew, J. S.; Hu, Y.; Ramdas, L.; Hu, L.; Keating, M. J.; Zhang, W.; Plunkett, W.; Huang, P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J. Cell Biol. 2006, 175, 913-923.
147. Levit, M.N.; Stock, J.B. pH sensing in bacterial chemotaxis. Novartis Found. Symp. 1999, 221, 38-50.
148. Yu, Q.; Heikal, A. A. Two-photon autofluorescence dynamics imaging reveals sensitivity of intracellular NADH concentration and conformation to cell physiology at the single-cell level. J. Photochem. Photobiol. B 2009, 95, 46-57.
149. Bird, D. K.; Yan, L.; Vrotsos, K. M.; Eliceiri, K. W.; Vaughan, E. M.; Keely, P. J.; White, J. G.; Ramanujam, N. Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. Cancer Res. 2005, 65, 8766-8773.
150. Ganapathy, V.; Thangaraju, M.; Prasad, P. D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009, 121, 29-40.
151. Boyer, M. J.; Tannock, I. F. Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res. 1992, 52, 4441-4447.
152. Lee, A. H.; Tannock, I. F. Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res. 1998, 58, 1901-1908.
153. Stubbs, M.; Rodrigues, L.; Howe, F. A.; Wang, J.; Jeong, K. S.; Veech, R. L.; Griffiths, J. R. Metabolic consequences of a reversed pH gradient in rat tumors. Cancer Res. 1994, 54, 4011-4016.
154. Tannock, I. F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49, 4373-4384.
155. Wike-Hooley, J. L.; Haveman, J.; Reinhold, H. S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 1984, 2, 343-366.
156. Castaing, M.; Loiseau, A.; Dani, M. Designing multidrugresistance modulators circumventing the reverse pH gradient in tumours. J. Pharm. Pharmacol. 2001, 53, 1021-1028.
157. Wapnir, R. A. Copper absorption and bioavailability. Am. J. Clin. Nutr. 1998, 67, 1054S-1060S.
158. Sturniolo, G. C.; Montino, M. C.; Rossetto, L.; Martin, A.; D'Inca, R.; D'Odorico, A.; Naccarato, R. Inhibition of gastric acid secretion reduces zinc absorption in man. J. Am. Coll. Nutr. 1991, 10, 372-375.
159. Penaud, S.; Fernandez, A.; Boudebbouze, S.; Ehrlich, S. D.; Maguin, E.; van de, G. M. Induction of heavy-metal-transporting CPX-type ATPases during acid adaptation in Lactobacillus bulgaricus. Appl. Environ. Microbiol. 2006, 72, 7445-7454.
160. Battistuzzi, G.; Borsari, M.; Canters, G. W.; de Waal, E.; Leonardi, A.; Ranieri, A.; Sola, M. Thermodynamics of the acid transition in blue copper proteins. Biochemistry 2002, 41, 14293-14298.
161. Byerly, L.; Suen, Y. Characterization of proton currents in neurones of the snail, Lymnaea stagnalis. J. Physiol. 1989, 413, pp. 75-89.
162. DeCoursey, T. E. Hydrogen ion currents in rat alveolar epithelial cells. Biophys. J. 1991, 60, 1243-1253.
163. Kramhoft, B.; Lambert, I. H.; Hoffmann, E. K. Na+/H+ exchange in Ehrlich ascites tumor cells: activation by cytoplasmic acidification and by treatment with cupric sulphate. J. Membr. Biol. 1988, 102, 35-48.
164. Larsen, A. K.; Escargueil, A. E.; Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 2000, 85, 217-229.
165. Pamp, K.; Bramey, T.; Kirsch, M.; De Groot, H.; Petrat, F. NAD(H) enhances the Cu(II)-mediated inactivation of lactate dehydrogenase by increasing the accessibility of sulfhydryl groups. Free Radic. Res. 2005, 39, 31-40.
166. Koiri, R. K.; Trigun, S. K.; Dubey, S. K.; Singh, S.; Mishra, L. Metal Cu(II) and Zn(II) bipyridyls as inhibitors of lactate dehydrogenase. Biometals 2008, 21, 117-126.
167. Costello, L. C.; Liu, Y.; Zou, J.; Franklin, R. B. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J. Biol. Chem. 1999, 274, 17499-17504.
168. Murata, N.; Mogi, C.; Tobo, M.; Nakakura, T.; Sato, K.; Tomura, H.; Okajima, F. Inhibition of superoxide anion production by extracellular acidification in neutrophils. Cell Immunol. 2009, 259, 21-26.
169. Wu, M. L.; Tsai, K. L.; Wang, S. M.; Wu, J. C.; Wang, B. S.; Lee, Y. T. Mechanism of hydrogen peroxide and hydroxyl free radicalinduced intracellular acidification in cultured rat cardiac myoblasts. Circ. Res. 1996, 78, 564-572.
170. Clement, M. V.; Ponton, A.; Pervaiz, S. Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. FEBS Lett. 1998, 440, 13-18.
171. Jancic, C.; Savina, A.; Wasmeier, C.; Tolmachova, T.; El Benna, J.; Dang, P. M.; Pascolo, S.; Gougerot-Pocidalo, M. A.; Raposo, G.; Seabra, M. C.; Amigorena, S. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat. Cell Biol. 2007, 9, 367-378.
172. Shao, M. X.; Nadel, J. A. Dual oxidase 1-dependent MUC5AC mucin expression in cultured human airway epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 767-772.
173. Ahmad, K. A.; Iskandar, K. B.; Hirpara, J. L.; Clement, M. V.; Pervaiz, S. Hydrogen peroxide-mediated cytosolic acidification is a signal for mitochondrial translocation of Bax during drug-induced apoptosis of tumor cells. Cancer Res. 2004, 64, 7867-7878.
174. Kong, Q.; Beel, J. A.; Lillehei, K. O. A threshold concept for cancer therapy. Med. Hypotheses 2000, 55, 29-35.
175. Ramanathan, B.; Jan, K. Y.; Chen, C. H.; Hour, T. C.; Yu, H. J.; Pu, Y. S. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res. 2005, 65, 8455-8460.
176. Sandhya, T.; Mishra, K. P. Cytotoxic response of breast cancer cell lines, MCF 7 and T 47 D to triphala and its modification by antioxidants. Cancer Lett. 2006, 238, 304-313.
177. Kozin, S. V.; Shkarin, P.; Gerweck, L. E. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res. 2001, 61, 4740-4743.
178. Mahoney, B. P.; Raghunand, N.; Baggett, B.; Gillies, R. J. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol. 2003, 66, 1207-1218.
179. Greijer, A. E.; de Jong, M. C.; Scheffer, G. L.; Shvarts, A.; van Diest, P. J.; van der, W. E. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol. 2005, 27, 43-49.
180. Gonzalez, M. J.; Mora, E. M.; Miranda-Massari, J. R.; Matta, J.; Riordan, H. D.; Riordan, N. H. Inhibition of human breast carcinoma cell proliferation by ascorbate and copper. P. R. Health Sci. J. 2002, 21, 21-23.
181. Kovacic, P.; Somanathan, R. Ototoxicity and noise trauma: electron transfer, reactive oxygen species, cell signaling, electrical effects, and protection by antioxidants: practical medical aspects. Med. Hypotheses 2008, 70, 914-923.
182. Valko, M.; Rhodes, C. J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160, 1-40.
183. Kang, Y. H.; Lee, E.; Choi, M. K.; Ku, J. L.; Kim, S. H.; Park, Y. G.; Lim, S. J. Role of reactive oxygen species in the induction of apoptosis by alpha-tocopheryl succinate. Int. J. Cancer 2004, 112, 385-392.
184. Milacic, V.; Fregona, D.; Dou, Q. P. Gold complexes as prospective metal-based anticancer drugs. Histol. Histopathol. 2008, 23, 101-108.
185. Hindo, S. S.; Frezza, M.; Tomco, D.; Heeg, M. J.; Hryhorczuk, L.; McGarvey, B. R.; Dou, Q. P.; Verani, C. N. Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome. Eur. J. Med. Chem. 2009, 44, 4353-4361.
186. Carraway, H.; Hidalgo, M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 2004, 6, 219-224.
187. Martin, D.; Salinas, M.; Fujita, N.; Tsuruo, T.; Cuadrado, A. Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B. J. Biol. Chem. 2002, 277, 42943-42952.
188. Wang, X.; McCullough, K. D.; Franke, T. F.; Holbrook, N. J. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J. Biol. Chem. 2000, 275, 14624-14631.
189. Ahmed, M. U.; Hazeki, K.; Hazeki, O.; Katada, T.; Ui, M. Cyclic AMP-increasing agents interfere with chemoattractant-induced respiratory burst in neutrophils as a result of the inhibition of phosphatidylinositol 3-kinase rather than receptor-operated Ca2+ influx. J. Biol. Chem. 1995, 270, 23816-23822.
190. Bae, Y. S.; Sung, J. Y.; Kim, O. S.; Kim, Y. J.; Hur, K. C.; Kazlauskas, A.; Rhee, S. G. Platelet-derived growth factor-induced H(2)O(2) production requires the activation of phosphatidylinositol 3-kinase. J. Biol. Chem. 2000, 275, 10527-10531.
191. Chen, Q.; Powell, D. W.; Rane, M. J.; Singh, S.; Butt, W.; Klein, J. B.; McLeish, K. R. Akt phosphorylates p47phox and mediates respiratory burst activity in human neutrophils. J. Immunol. 2003, 170, 5302-5308.
192. Goldshmit, Y.; Erlich, S.; Pinkas-Kramarski, R. Neuregulin rescues PC12-ErbB4 cells from cell death induced by H(2)O(2). Regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase. J. Biol. Chem. 2001, 276, 46379-46385.
193. Poh, T. W.; Pervaiz, S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res. 2005, 65, 6264-6274.
194. Lee, C. M.; Fuhrman, C. B.; Planelles, V.; Peltier, M. R.; Gaffney, D. K.; Soisson, A. P.; Dodson, M. K.; Tolley, H. D.; Green, C. L.; Zempolich, K. A. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin. Cancer Res. 2006, 12, 250-256.
195. Nicholson, K. M.; Quinn, D. M.; Kellett, G. L.; Warr, J. R. LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multidrug resistant cells. Cancer Lett. 2003, 190, 31-36.
196. Kondapaka, S. B.; Singh, S. S.; Dasmahapatra, G. P.; Sausville, E. A.; Roy, K. K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. 2003, 2, 1093-1103.
197. Chun, K. H.; Kosmeder, J. W.; Sun, S.; Pezzuto, J. M.; Lotan, R.; Hong, W. K.; Lee, H. Y. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl. Cancer Inst. 2003, 95, 291-302.
198. Rahmani, M.; Reese, E.; Dai, Y.; Bauer, C.; Payne, S. G.; Dent, P.; Spiegel, S.; Grant, S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 2005, 65, 2422-2432.
199. deGraffenried, L. A.; Friedrichs, W. E.; Russell, D. H.; Donzis, E. J.; Middleton, A. K.; Silva, J. M.; Roth, R. A.; Hidalgo, M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res. 2004, 10, 8059-8067.
200. Zhang, H.; Chen, D.; Ringler, J.; Chen, W.; Cui, Q. C.; Ethier, S. P.; Dou, Q. P.; Wu, G. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res. 2010, 70, 3996-4004.
201. Chen, D.; Cui, Q. C.; Yang, H.; Dou, Q. P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006, 66, 10425-10433.
202. Budman, D. R.; Calabro, A. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res. Treat. 2002, 74, 41-46.
203. Koshida, R.; Ou, J.; Matsunaga, T.; Chilian, W. M.; Oldham, K. T.; Ackerman, A. W.; Pritchard, K. A., Jr. Angiostatin: a negative regulator of endothelial-dependent vasodilation. Circulation 2003, 107, 803-806.
204. Chew, E. H.; Nagle, A. A.; Zhang, Y.; Scarmagnani, S.; Palaniappan, P.; Bradshaw, T. D.; Holmgren, A.; Westwell, A. D. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radic. Biol. Med. 2010, 48, 98-111.
205. Lee, H. S.; Lee, S. Y.; Ha, H. L.; Han, D. C.; Han, J. M.; Jeong, T. S.; Yu, D. Y.; Yeom, Y. I.; Kwon, B. M.; Moon, E. Y. 2'-Benzoyloxycinnamaldehyde inhibits tumor growth in H-ras12V transgenic mice via downregulation of metallothionein. Nutr. Cancer 2009, 61, 723-734.
206. Uthman, A.; Rezaie, S.; Dockal, M.; Ban, J.; Soltz-Szots, J.; Tschachler, E. Fluconazole downregulates metallothionein expression and increases copper cytotoxicity in Microsporum canis. Biochem. Biophys. Res. Commun. 2002, 299, 688-692.
207. Davies, G. F.; Ross, A. R.; Arnason, T. G.; Juurlink, B. H.; Harkness, T. A. Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Lett. 2010, 288, 236-250.
208. Girnun, G. D.; Naseri, E.; Vafai, S. B.; Qu, L.; Szwaya, J. D.; Bronson, R.; Alberta, J. A.; Spiegelman, B. M. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 2007, 11, 395-406.
209. Cantini, G.; Lombardi, A.; Piscitelli, E.; Poli, G.; Ceni, E.; Marchiani, S.; Ercolino, T.; Galli, A.; Serio, M.; Mannelli, M.; Luconi, M. Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res. 2008, 2008, 904041.
210. Farrow, B.; Evers, B. M. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2003, 301, 50-53.
211. Lee, S. Y.; Hur, G. Y.; Jung, K. H.; Jung, H. C.; Lee, S. Y.; Kim, J. H.; Shin, C.; Shim, J. J.; In, K. H.; Kang, K. H.; Yoo, S. H. PPARgamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 2006, 51, 297-301.
212. Bonofiglio, D.; Gabriele, S.; Aquila, S.; Catalano, S.; Gentile, M.; Middea, E.; Giordano, F.; Ando, S. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin. Cancer Res. 2005, 11, 6139-6147.
213. Beauchamp, C.; Fridovich, I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 1971, 44, 276-287.